Investor Presentaiton

Next-gen Cell Therapy pipeline: Oncology, Immunology, and Allogenic Hematology Early Discovery Late Discovery IND-Enabling Development Approved Breyanzi Abecma 2seventybio Partnered BMS-986393 GPRC5D CART (MM) ll Bristol Myers Squibb™ BCMAXGPRC5D CART (MM); Bristol Myers Squibb™ Allo Eng CART (NHL) Bristol Myers Squibb™ iPSC-derived iT/INK (AML) CENTURY Partnered THERAPEUTICS iPSC-derived iT/INK (MM) Discuss today. Immunology Oncology Eng Treg (IBD) CD19 NEXT (Multiple autoimmune disorders); Bristol Myers Squibb Next-gen CART (Multiple autoimmune disorders) Bristol Myers Squibb™ gentibio Partnered Allo Eng gd eTCR T (solid tumors) Logic-gated CAR T Program 1 (indication not disclosed) Logic-gated CART Program 2 (indication not disclosed) Allo Eng CART (RCC) ll Bristol Myers Squibb™ immatics Partnered O -ArsenalBio Partnered ll Bristol Myers Squibb Cell Therapy Platform: Autologous Allogeneic Not disclosed Cell Engineering Technologies: О editas CRISPR engineered program MEDICINE Ill Bristol Myers Squibb™ Multiple Eng CAR T Programs Multiple Eng eTCR T Programs Ill Bristol Myers Squibb Immatics OBSIDIAN Immune payloading programs not disclosed Not for Product Promotional Use 45

View entire presentation